Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

医学 替莫唑胺 内科学 佐剂 临床研究阶段 临床终点 不利影响 生存素 外科 肿瘤科 化疗 临床试验 无进展生存期 放射治疗 胃肠病学 癌症
作者
Manmeet S. Ahluwalia,David A. Reardon,Ajay Abad,William T. Curry,Eric T. Wong,Sheila Figel,Laszlo Mechtler,David M. Peereboom,Alan D. Hutson,Henry Withers,Song Liu,Ahmed Belal,Jingxin Qiu,Kathleen Mogensen,Sanam Dharma,Andrew Dhawan,Meaghan Birkemeier,Danielle Casucci,Michael J. Ciesielski,Robert A. Fenstermaker
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:41 (7): 1453-1465 被引量:57
标识
DOI:10.1200/jco.22.00996
摘要

PURPOSE Despite intensive treatment with surgery, radiation therapy, temozolomide (TMZ) chemotherapy, and tumor-treating fields, mortality of newly diagnosed glioblastoma (nGBM) remains very high. SurVaxM is a peptide vaccine conjugate that has been shown to activate the immune system against its target molecule survivin, which is highly expressed by glioblastoma cells. We conducted a phase IIa, open-label, multicenter trial evaluating the safety, immunologic effects, and survival of patients with nGBM receiving SurVaxM plus adjuvant TMZ following surgery and chemoradiation (ClinicalTrials.gov identifier: NCT02455557 ). METHODS Sixty-four patients with resected nGBM were enrolled including 38 men and 26 women, in the age range of 20-82 years. Following craniotomy and fractionated radiation therapy with concurrent TMZ, patients received four doses of SurVaxM (500 μg once every 2 weeks) in Montanide ISA-51 plus sargramostim (granulocyte macrophage colony-stimulating factor) subcutaneously. Patients subsequently received adjuvant TMZ and maintenance SurVaxM concurrently until progression. Progression-free survival (PFS) and overall survival (OS) were reported. Immunologic responses to SurVaxM were assessed. RESULTS SurVaxM plus TMZ was well tolerated with no serious adverse events attributable to SurVaxM. Of the 63 patients who were evaluable for outcome, 60 (95.2%) remained progression-free 6 months after diagnosis (prespecified primary end point). Median PFS was 11.4 months and median OS was 25.9 months measured from first dose of SurVaxM. SurVaxM produced survivin-specific CD8+ T cells and antibody/immunoglobulin G titers. Apparent clinical benefit of SurVaxM was observed in both methylated and unmethylated patients. CONCLUSION SurVaxM appeared to be safe and well tolerated. The combination represents a promising therapy for nGBM. For patients with nGBM treated in this manner, PFS may be an acceptable surrogate for OS. A large randomized clinical trial of SurVaxM for nGBM is in progress.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
英俊的铭应助研友_Z1xNWn采纳,获得30
刚刚
souther完成签到,获得积分0
刚刚
浮华应助崔尔蓉采纳,获得10
刚刚
刚刚
1秒前
九枝。给九枝。的求助进行了留言
1秒前
1秒前
cccc完成签到,获得积分10
2秒前
2秒前
vippp发布了新的文献求助10
3秒前
3秒前
4秒前
zxc发布了新的文献求助10
5秒前
宋佳完成签到,获得积分20
6秒前
Steplan完成签到 ,获得积分10
6秒前
dingyanxia发布了新的文献求助10
6秒前
7秒前
7秒前
LLLLLLL1471完成签到,获得积分20
7秒前
笑、完成签到,获得积分10
7秒前
7秒前
积极天思应助lou采纳,获得10
8秒前
帅气面包完成签到 ,获得积分10
8秒前
羊皮大哈发布了新的文献求助10
9秒前
shengdong完成签到,获得积分10
9秒前
tomato039发布了新的文献求助10
9秒前
1234发布了新的文献求助20
10秒前
调研昵称发布了新的文献求助10
11秒前
12秒前
明理的夜雪完成签到,获得积分20
12秒前
13秒前
ptalala完成签到,获得积分10
13秒前
活力笑天完成签到,获得积分20
14秒前
15秒前
彭于晏应助zxc采纳,获得10
17秒前
星辰大海应助dingyanxia采纳,获得30
17秒前
splatoon发布了新的文献求助10
17秒前
18秒前
祗想静静嘚完成签到,获得积分10
18秒前
ZZRR发布了新的文献求助10
19秒前
高分求助中
Sustainability in Tides Chemistry 2000
Microlepidoptera Palaearctica, Volumes 1 and 3 - 13 (12-Volume Set) [German] 1122
Дружба 友好报 (1957-1958) 1000
The Data Economy: Tools and Applications 1000
Mantiden - Faszinierende Lauerjäger – Buch gebraucht kaufen 700
PraxisRatgeber Mantiden., faszinierende Lauerjäger. – Buch gebraucht kaufe 700
A Dissection Guide & Atlas to the Rabbit 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3101245
求助须知:如何正确求助?哪些是违规求助? 2752689
关于积分的说明 7620005
捐赠科研通 2404773
什么是DOI,文献DOI怎么找? 1275998
科研通“疑难数据库(出版商)”最低求助积分说明 616673
版权声明 599058